Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ferguson

Showing results (301-310 of 739) with videos related to

Pageof 74
Sort By:
Respiratory Medicine|October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocolKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Materials (Basel, Switzerland)|June 27, 2024
Optical, Structural, and Synchrotron X-ray Absorption Studies for GaN Thin Films Grown on Si by Molecular Beam EpitaxyZhe Chuan Feng, Jiamin Liu, Deng Xie, et al.
The Journal of Nutrition|November 22, 2007
Characterization of proteomic and metabolomic responses to dietary factors and supplementsJohn Astle, Jonathan T Ferguson, J Bruce German, et al.
Lancet (London, England)|September 10, 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialJ Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, et al.
Advanced Nanobiomed Research|June 2, 2023
Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar DiseasesLaura T Ferguson, Xiaonan Ma, Jacob W Myerson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS StudyMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPDMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
International Journal of Molecular Sciences|January 23, 2024
The Anticancer Effects of the Garlic Organosulfide Diallyl Trisulfide through the Attenuation of B[a]P-Induced Oxidative Stress, AhR Expression, and DNA Damage in Human Premalignant Breast Epithelial (MCF-10AT1) CellsDominique T Ferguson, Equar Taka, Syreeta L Tilghman, et al.
Respiratory Research|September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDLeonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
Pageof 74

Showing results (301-310 of 739) with videos related to

Sort By:
Pageof 74
Respiratory Medicine|October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocolKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Materials (Basel, Switzerland)|June 27, 2024
Optical, Structural, and Synchrotron X-ray Absorption Studies for GaN Thin Films Grown on Si by Molecular Beam EpitaxyZhe Chuan Feng, Jiamin Liu, Deng Xie, et al.
The Journal of Nutrition|November 22, 2007
Characterization of proteomic and metabolomic responses to dietary factors and supplementsJohn Astle, Jonathan T Ferguson, J Bruce German, et al.
Lancet (London, England)|September 10, 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialJ Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, et al.
Advanced Nanobiomed Research|June 2, 2023
Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar DiseasesLaura T Ferguson, Xiaonan Ma, Jacob W Myerson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS StudyMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPDMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
International Journal of Molecular Sciences|January 23, 2024
The Anticancer Effects of the Garlic Organosulfide Diallyl Trisulfide through the Attenuation of B[a]P-Induced Oxidative Stress, AhR Expression, and DNA Damage in Human Premalignant Breast Epithelial (MCF-10AT1) CellsDominique T Ferguson, Equar Taka, Syreeta L Tilghman, et al.
Respiratory Research|September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDLeonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
Pageof 74